Lateral paracapsular GABAergic synapses in the basolateral amygdala contribute to the anxiolytic effects of beta 3 adrenoceptor activation.
Norepinephrine (NE) is known to play an integral role in the neurobiological response to stress. Exposure to stressful stimuli increases NE levels in brain regions that regulate stress and anxiety, like the basolateral amygdala (BLA). NE is thought to increase excitability in these areas through alpha- and beta-adrenoceptors (ARs), leading to increased anxiety. Surprisingly, recent studies have shown that systemic beta 3-AR agonist administration decreases anxiety-like behaviors, suggesting that beta 3-ARs may inhibit excitability in anxiety-related brain regions. Therefore, in this study we integrated electrophysiological and behavioral approaches to test the hypothesis that the anxiolytic effects of beta 3-AR agonists may be mediated by an increase in BLA GABAergic inhibition. We examined the effect of a selective beta 3-AR agonist, BRL37344 (BRL), on GABAergic synapses arising from local circuit interneurons and inhibitory synapses originating from a recently described population of cells called lateral paracapsular (LPCS) interneurons. Surprisingly, BRL selectively enhanced LPCS-evoked inhibitory postsynaptic currents (eIPSCs) with no effect on local GABAergic inhibition. BRL also had no effect on glutamatergic synaptic excitation within the BLA. BRL potentiation of LPCS eIPSCs was blocked by the selective beta 3-AR antagonist, SR59230A, or by intracellular dialysis of Rp-CAMPS (cAMP-dependent protein kinase inhibitor), and this enhancement was not associated with any changes in spontaneous IPSCs or LPCS paired-pulse ratio. BRL also increased the amplitude of unitary LPCS IPSCs (uIPSCs) with no effect on uIPSC failure rate. Finally, bilateral BLA microinjection of BRL reduced anxiety-like behaviors in an open-field assay and the elevated plus-maze. Collectively, these data suggest that beta 3-AR activation selectively enhances LPCS, but not local, BLA GABAergic synapses, and that increases in LPCS-mediated inhibition may contribute to the anxiolytic profile of beta 3-AR agonists.
Silberman
Yuval
Y
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
Ariwodola
Olusegun J
OJ
Chappell
Ann M
AM
Yorgason
Jordan T
JT
Weiner
Jeff L
JL
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000679:Amygdala / Q000166:cytology*; D000818:Animals; D001007:Anxiety / Q000188:drug therapy* / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004983:Ethanolamines / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005106:Exploratory Behavior / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects; D007395:Interneurons / Q000187:drug effects; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008845:Microinjections / Q000379:methods; D009025:Morpholines / Q000494:pharmacology; D018408:Patch-Clamp Techniques / Q000379:methods; D011433:Propranolol / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D022702:Receptors, Adrenergic, beta-3 / Q000378:metabolism*; D013569:Synapses / Q000187:drug effects* / Q000378:metabolism*; D013873:Thionucleotides / Q000494:pharmacology; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
C095804:(+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists; D009025:Morpholines; D047428:Protein Kinase Inhibitors; D022702:Receptors, Adrenergic, beta-3; D013873:Thionucleotides; C016957:adenosine-3',5'-cyclic phosphorothioate; D005680:gamma-Aminobutyric Acid; C057368:BRL 37344; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D011433:Propranolol; D000242:Cyclic AMP
J Pharmacol Exp Ther. 2008 Jan;324(1):251-60
17921186
Brain Res Mol Brain Res. 1995 Apr;29(2):369-75
7609625
Neuropsychopharmacology. 2009 Jan;34(2):410-23
18536707
Endocrinology. 2003 Feb;144(2):594-8
12538621
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1399-419
18495312
Annu Rev Neurosci. 2004;27:1-28
15217324
Brain Res. 1980 May 26;190(2):347-68
6768425
Neuropharmacology. 2004 Jun;46(7):1018-22
15081798
Neurosci Biobehav Rev. 1999 Nov;23(7):971-80
10580311
J Pharmacol Exp Ther. 2009 Sep;330(3):704-17
19515967
J Neurosci. 2004 Nov 24;24(47):10679-86
15564584
Brain Res. 1996 Sep 2;732(1-2):145-53
8891278
Neurosci Lett. 1991 Dec 16;134(1):139-44
1815147
Neuropharmacology. 2008 Oct;55(5):661-8
18617194
Neuroscience. 2008 Dec 10;157(4):781-97
18950687
Cell Mol Neurobiol. 2003 Oct;23(4-5):727-38
14514027
Neuropsychopharmacology. 2008 Feb;33(3):574-87
17460614
Pharmacol Ther. 2005 Jul;107(1):80-98
15963352
Neurosci Biobehav Rev. 1999 Mar;23(4):591-613
10073896
J Comp Neurol. 1978 Aug 1;180(3):509-32
659673
J Neurosci. 2003 Jul 30;23(17):6754-8
12890768
Eur J Neurosci. 2008 Sep;28(5):849-61
18691332
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1214-24
16226365
Behav Brain Res. 2007 Mar 12;178(1):70-81
17207866
J Neurophysiol. 1996 Oct;76(4):2626-34
8899633
J Clin Endocrinol Metab. 2005 Oct;90(10):5786-96
16014404
Pharmacol Biochem Behav. 1995 Dec;52(4):701-6
8587908
Br J Pharmacol. 2005 Feb;144(3):317-22
15655528
Br J Pharmacol. 1995 Nov;116(6):2547-8
8590968
Neurobiol Learn Mem. 2006 Sep;86(2):123-32
16458544
Brain Res. 2008 May 13;1209:65-73
18396264
Pharmacol Res. 2009 Apr;59(4):221-34
19429463
Neuropharmacology. 2009 Apr;56(5):886-95
19371578
J Neurophysiol. 2005 Dec;94(6):4491-501
16162835
Nature. 1984 May 10-16;309(5964):163-5
6325935
Annu Rev Med. 1997;48:307-16
9046964
Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):385-98
17211601
Brain Res. 1995 Feb 13;671(2):213-21
7743210
Psychopharmacology (Berl). 1993;110(1-2):240-4
7870892
Am J Physiol Cell Physiol. 2008 Nov;295(5):C1344-53
18799656
J Pharmacol Exp Ther. 1996 Apr;277(1):22-7
8613923
Eur J Pharmacol. 2007 Nov 14;573(1-3):139-47
17669397
Eur J Neurosci. 2007 Aug;26(4):1036-44
17666080
Braz J Med Biol Res. 2005 Nov;38(11):1697-701
16258641
J Neurosci. 1981 Jan;1(1):49-59
6286893
Neuropsychopharmacology. 2005 Apr;30(4):657-68
15602500
Eur J Neurosci. 2009 Sep;30(5):800-7
19712089
Pharmacol Ther. 2006 Sep;111(3):652-73
16480771
Hippocampus. 2008;18(11):1131-9
18680159
J Neurosci. 1999 Jun 15;19(12):5119-23
10366644
Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33
12600700
Psychopharmacology (Berl). 1990;102(1):98-101
1975449
Trends Neurosci. 1994 May;17(5):208-14
7520203
J Neurosci. 2003 Jan 15;23(2):442-52
12533604
Eur J Pharmacol. 2006 Jan 20;530(3):263-9
16388799
Nature. 1994 Oct 20;371(6499):704-7
7935816
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18338-43
17101972
Synapse. 1996 May;23(1):28-38
8723133
J Neurosci. 2007 Jan 17;27(3):553-63
17234587
Neuroscience. 2007 Sep 7;148(3):737-43
17706366
Neuroscience. 2008 Oct 2;156(2):353-64
18691638
J Physiol. 2000 Jul 1;526 Pt 1:3-11
10878094
Neuron. 2005 Dec 22;48(6):1025-37
16364905